Floatz logo

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS MIF (MACROPHAGE MIGRATION INHIBITORY FACTOR, GLYCOSYLATION-INHIBITING FACTOR, GLIF, GIF)), HOMO SAPIENS MONOCLONAL ANTIBODY

Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

Baxalta now part of Shiremonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

525 Active assets in the Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS MIF (MACROPHAGE MIGRATION INHIBITORY FACTOR, GLYCOSYLATION-INHIBITING FACTOR, GLIF, GIF)), HOMO SAPIENS MONOCLONAL ANTIBODY is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →